Evidence map›Paper›PMID 39306828›Full record

ArticleJournal of neurology2024

Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data.

Tatjana Pekmezovic, Vanja Jovicevic, Marko Andabaka, Nikola Momcilovic, Nikola Veselinovic, Olivera Tamas, Maja Budmkic, Stefan Todorovic, Marta Jeremic, Evica Dincic and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tatjana PekmezovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia. pekmezovic@sezampro.rs.ORCID http://orcid.org/0000-0001-7978-1409
Vanja JovicevicClinic of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Marko AndabakaClinic of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Nikola MomcilovicClinic of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Nikola VeselinovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia.
Olivera TamasInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia.
Maja BudmkicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia.
Stefan TodorovicClinic of Neurology, Faculty of Medicine, Clinical Center Nis, University of Nis, Nis, Serbia.
Marta JeremicClinic of Neurology, University Clinical Center of Serbia, Belgrade, Serbia.
Evica DincicClinic of Neurology, Military Medical Academy, Medical Faculty, Defense University, Belgrade, Serbia.
Slobodan VojinovicClinic of Neurology, Faculty of Medicine, Clinical Center Nis, University of Nis, Nis, Serbia.
Sladjana AndrejevicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia.
Sarlota MesarosInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia.
Jelena DrulovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, 11000, Belgrade, Serbia.

Funding

Wellcome Trust 200110
6 · The paper itself

Abstract

backgroundThe aim of our study was to estimate the frequency of autoimmune comorbidities, in NMOSD patients from the national Serbian NMOSD Registry.

methodsOur study comprises 136 patients with NMOSD, diagnosed according to the NMOSD criteria 2015. At the time of the study, in the Registry were collected demographic and clinical data, including those related to the coexisting comorbidities and pathogenic autoantibodies. Not all patients were tested for all autoimmune antibodies. None of the seronegative aquaporin4-IgG (AQP4-IgG) NMOSD patients, included in the Registry, were positive for the myelin oligodendrocyte glycoprotein IgG.

resultsAmong 136 NMOSD patients, 50 (36.8%) had at least one associated autoimmune disorder. AQP4-IgG was present in the sera from 106 patients (77.9%), the proportion of NMOSD patients with autoimmune comorbidities being significantly higher in the AQP4-IgG positive subgroup in comparison to the AQP4-IgG negative (p = 0.002). AQP4-IgG seropositive NMOSD patients had 5.2-fold higher risk of comorbid autoimmune diseases (OR = 5.2, 95% CI 1.4-18.5, p = 0.012). The most frequently reported diseases were autoimmune thyroid disease (15.4%), Sjogren's syndrome (11.0%), systemic lupus erythematosus (5.1%), myasthenia gravis (4.4%), and primary antiphospholipid antibody syndrome (2.9%). Antinuclear antibodies (ANAs) were frequently detected in the subgroup of NMOSD patients tested for this antibody (50/92; 54.3%). The higher frequency of ANAs and anti-extractable nuclear antigen autoantibodies, in the subgroups of AQP4-IgG-positive patients compared to the AQP4-IgG negative, tested for these antibodies, was statistically significant (p = 0.009, and p = 0.015, respectively).

conclusionIn conclusion, based on our results, in a defined cohort with European ethnical background, a wide spectrum of autoimmune diseases is frequently associated with AQP4-IgG seropositive NMOSD patients.

Indexed as

Aquaporin 4AutoantibodiesAutoimmune DiseasesComorbidityImmunoglobulin GNeuromyelitis OpticaRegistriesAdultAgedFemaleHumansMaleMiddle AgedSerbiaYoung AdultAQP4 protein, humanAquaporin 4AutoantibodiesImmunoglobulin GAutoimmune comorbidityAutoimmune thyroid diseaseMyasthenia gravisNeuromyelitis optica spectrum disorderPathogenic autoantibodiesSjogren’s syndromeSystemic lupus erythematosus

Identifiers

PMID39306828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.